Koichi Takahashi, M.D., Ph.D.
Department of Leukemia, Division of Cancer Medicine
About Dr. Takahashi
Dr. Takahashi earned MD degree from Niigata University School of Medicine, Japan in 2006. He then completed two internal medicine residency, the first one in Toranomon Hospital, Tokyo, and the second in Beth Israel Medical Center, New York. He came to MD Anderson Cancer Center in 2011 as an Hematology/Oncology fellow and completed fellowship in 2014. During this time, Dr. Takahashi did postdoctoral fellowship under the mentorship of Dr. Andrew Futreal. He is board certified in Internal Medicine, Hematology and Medical Oncology. Currently, Dr. Takahashi is a Tenured Associate Professor in the Department of Leukemia with a joint appointment at the Department of Genomic Medicine. He is a physician-scientist focusing on studying pathogenesis of therapy-related myeloid neoplasms, and clonal evolution of myeloid neoplasms.
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Associate Professor, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
Acute Myeloid Leukemia
Myelodysplastic syndromes
Therapy-related myeloid neoplasms
Clonal hematopoiesis
Genomics
Clinical Interests
AML
Clonal hematopoiesis
Therapy-related myeloid neoplasms
MDS
Education & Training
Degree-Granting Education
| 2020 | Kyoto University, Kyoto, JP, Ph.D. in Medicine |
| 2006 | Niigata University Faculty of Medicine, Niigata, JP, MD |
Postgraduate Training
| 2011-2014 | Clinical Fellowship, Hematology/Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas |
| 2008-2011 | Clinical Residency, Internal Medicine, Beth Israel Medical Center, New York, New York |
| 2006-2008 | Clinical Residency, Internal Medicine, Toranomon Hospital, Tokyo |
Licenses & Certifications
| 2014 | American Board of Hematology |
| 2014 | American Board of Medical Oncology |
| 2011 | American Board of Internal Medicine |
Experience & Service
Faculty Academic Appointments
Assistant Professor, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015 - 2021
Assistant Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 2014 - 2021
Other Professional Positions
Co-founder and Chair, Beth Israel Research Society, New York, NY, 2010 - 2011
Institutional Committee Activities
Member, Moonshot Internal Advisory Board, 2022 - Present
Member, MD Anderson's Core Facility Oversight Board, 2022 - 2025
Member, Breakthroughs Advisory Council, 2022 - Present
Member, Breakthroughs Advisory Council, 2022 - Present
Member, Senate Academic Planning Committee, 2021 - Present
Member, Decisive Discoveries Focus Working Group "Key Knowledge Gaps in Biology", 2017 - 2021
Member, Data and Biospecimen Access Committee, 2017 - 2020
Honors & Awards
| 2022 | Leukemia & Lymphoma Scholar Award |
| 2022 | Team Science Award, MD Anderson Cancer Center |
| 2021 | Team Science Award, MD Anderson Cancer Center |
| 2020 | Andrew Sabin Family Fellow |
| 2020 | Junior Faculty Scholar Award in Basic Translational Research, American Society of hematologyu |
| 2016 | Khalifa Scholar Physician Scientist Award, The University of Texas MD Anderson Cancer Center |
| 2014 | Travel Award, European Haematology Association |
| 2014 | Achievement in Basic Research Award, The University of Texas MD Anderson Cancer Center |
| 2014 | Merit Award, American Society of Clinical Oncology |
| 2014 | Research Training Award for Fellows, American Society of Hematology |
| 2013 | Abstract Achievement Award, American Society of Hematology |
| 2013 | The Kimberly Patterson Leukemia Research Fellowship |
| 2012 | Celgene Future Leaders in Hematology Award, Celgene |
| 2012 | The Janice Davis Singletary Fellowship of Lymphoma Research |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2021. Clonal Evolution and Heterogeneity of Acute Myeloid Leukemia. Conference. Clonal Evolution and Heterogeneity of Acute Myeloid Leukemia. Houston, TX, US.
- 2021. Reconstructing clonal evolution in AML. Conference. Reconstructing clonal evolution in AML. Houston, TX, US.
- 2021. Next generation MRD monitoring in AML”. Conference. Next generation MRD monitoring in AML”. Houston, TX, US.
- 2019. Genomics and environmental contribution for therapy-related myeloid neoplasms. Conference. Genomics and environmental contribution for therapy-related myeloid neoplasms. Houston, TX, US.
- 2019. Clinical and intratumor heterogeneitty of leukemia. Conference. Clinical and intratumor heterogeneitty of leukemia. Houston, TX, US.
- 2019. Think Tank for Clonal Hematopoiesis. Conference. Think Tank for Clonal Hematopoiesis. Houston, TX, US.
- 2019. Think Tank for clonal hematopoiesis. Conference. Think Tank for clonal hematopoiesis. Houston, TX, US.
Regional Presentations
- 2022. Texas Single-Cell Seminar. Conference. Texas Single-Cell Seminar, US.
- 2011. Distinct Clincal Characteristic of Myeloysplastic Syndrom in Human Immunodificienty Virus Infected Patients. Conference. Distinct Clincal Characteristic of Myeloysplastic Syndrom in Human Immunodificienty Virus Infected Patients. New York, NY, US.
- 2008. Granulomatosis Arteritis presented with Eosinophilic Myositis. Conference. Granulomatosis Arteritis presented with Eosinophilic Myositis, JP.
- 2007. IgA nephropathy with a clinical course of progressive renal failure. Conference. IgA nephropathy with a clinical course of progressive renal failure, JM.
National Presentations
- 2024. Approaches to leverage single-cell sequencing in understanding AML biology and response to therapy. Invited. iWAL 2024 - International Workshop on Acute Leukemias. Pheonix, Arizona, US.
- 2022. The Genetic Mechanism of Therapy-related Myeloid Neoplasms. Conference. The Genetic Mechanism of Therapy-related Myeloid Neoplasms. Virtual Format, US.
- 2022. The role of HIPK2 in therapy-related myeloid neoplasms. Conference. The role of HIPK2 in therapy-related myeloid neoplasms. Detroit, MI, US.
- 2022. Single-cell multiomics in AML. Conference. Single-cell multiomics in AML. Boston, MA, US.
- 2022. The impact of cancer chemotherapy on genome and somatic mutations of hematopoietic stem cells. Conference. The impact of cancer chemotherapy on genome and somatic mutations of hematopoietic stem cells. Boston, MA, US.
- 2022. Clonal hematopoiesis as a hidden driver of oncologic care outcomes. Conference. AACR. New Orleans, LA, US.
- 2022. Clonal heterogeneity and evolution of AML. Conference. Clonal heterogeneity and evolution of AML. San Diego, CA, US.
- 2021. Single-cell genomics and AML. Conference. 3rd Annual iwAL Workshop. Tampa, FL, US.
- 2021. Implications of Clonal Hematopoiesis in Human Health. Conference. AACR Annual Meeting 2021. Virtual, US.
- 2020. Single Cell Insights into Myeloid Neoplasia. Conference. AMP 2020 Annual Meeting & Expo: Virtual Education & Networking Experience. Virtual, US.
- 2020. Clonal heterogeneity and evolution of acute myeloid leukemia. Conference. AACR Virtual Special Conference: Tumor Heterogeneity: From Single Cells to Clinical Impact, US.
- 2020. The Spectrum of CLonal Hematopoeiesis from CHIP to AML. Conference. SOHO 2020. Houston, TX, US.
- 2019. Single-cell DNA sequencing delineates clonal diversity of AML. Conference. Single-cell DNA sequencing delineates clonal diversity of AML. Basel.
- 2019. Delineating clonal diversity of AML by single-cell genomics. Conference. Leukemia SPORE Career Enhancement Program. St. Louis, MO, US.
- 2019. Unraveling clonal heterogeneity and evolutionary history of AML by single-cell NDA sequencing. Conference. AACR Annual Meeting. Atlanta, GA, US.
- 2017. Next Steps with CHIP and Myeloid Neoplasms-Informing Risk and Prevention. Conference. 59th American Society of Hematology Annual Meeting. Atlanta, GA, US.
International Presentations
- 2024. EVI1 in Hematopoiesis. Invited. 86th Annual Meeting of the Japanese Society of Hematology. Kyoto, JP.
- 2023. On the frontline of research for hematologic malignancies. Invited. The 82nd Annual Meeting of the Japanese Cancer Association. Yokohama, JP.
- 2022. Molecular prognostication and genomics of newly diagnosed AML. Conference. 2022 AML Clinical Roadmap. London.
- 2022. Single-cell multiomics in Cancer. Conference. Single-cell multiomics in Cancer. Yokohoma, JP.
- 2022. Clonal hematopoiesis and AML. Conference. Clonal hematopoiesis and AML. Nice, FR.
- 2022. Clonal hematopoiesis and therapy-related myeloid neoplasms. Conference. JSTCT. Yokohama, JP.
- 2022. Clonal heterogeneity and evolution in AML. Conference. Japanese Society of Medical Oncology. Kyoto, JP.
- 2021. Clonal heterogeneity and evolution in AML. Conference. Japanese Society of Hematology. Sendai, JP.
- 2021. High throughput single cell analysis in AML. Conference. Korea Society of Blood and Marrow Transplant. Virtual.
- 2021. Diagnostic and Therapeutic Implications of Myeloid Gene Panel. Conference. Novartis. Virtual, KW.
- 2020. Precision clonal mapping in acute myeloid leukemia with single-cell genomics. Conference. D5 Medical & Life Science Seminar. Virtual, US.
- 2019. Clonal heterogeneity of AML and its clinical implications. Conference. Single Cell Symposium. Helsinki, FI.
- 2019. Clonal heterogeneity in AML. Conference. 6th Annual Global Summit on Hematologic Malignancies. Whistler, CA.
- 2019. Single-cell atlas of driver mutations in AML. Conference. Single cell Biology Meets Diagnostics. Uppsala, SE.
- 2019. Leukemic Potential of clonal hematopoiesis and the association with external stressors. Conference. Clonal Hematopoiesis Workshop. Hiroshima, JP.
Formal Peers
- 2022. Grand Rounds - Virtual. Invited. Augusta, GA, US.
- 2022. TBD. Invited, Ontario, CA.
- 2022. Leukemia Academic Rounds - Virtual. Invited. Toronto, CA.
- 2022. Evolutionary trajectories of clonal hematopoiesis to myeloid malignancy. Invited. Okayama, JP.
- 2021. ENJOY Science Webinar. Invited. Houston, TX, US.
- 2021. Clonal heterogeneity in AML. Invited. Boulder, CO, US.
- 2021. Determinants of clonal hematopoiesis developments and growth. Invited. Virtual, US.
- 2021. Evolutionary History of Preleukemia and Acute Myeloid Leukemia. Invited. Houston, TX, US.
- 2020. Can Unravelling Clonal Evolution in AML Help Guide Therapy with Today's Drugs?. Invited. Dallas, TX, US.
- 2019. Single-cell atlas of acute myeloid leukemia. Invited. Uppsala, SE.
- 2019. Clinical implications of clonal hematopoiesis. Invited. Hiroshima, JP.
- 2019. Clinical implications of clonal hematopoiesis. Invited. Hiroshima, JP.
- 2018. Evolution of AML genome and epigenome during therapy. Invited. Kumamoto, JP.
- 2017. Genomic landscape of acute mixed phenotype leukemia. Invited. Fukuoka, Fukuoka, JP.
- 2017. Genomic landscape of mixed phenotype acute leukemia. Invited. Tokyo, JP.
- 2017. Molecular diagnosis of MDS. Invited. Houston, TX, US.
- 2016. Clinical residency training abroad. Invited, JP.
- 2016. Clinical implications of clonal hematopoiesis. Invited, JP.
- 2016. Molecular diagnosis of MDS. Invited. Houston, TX, US.
- 2015. Molecular diagnosis of MDS. Invited. Houston, TX, US.
- 2014. Residency training and beyond. Invited, JP.
- 2014. Residency training and clinical research in Unisted States. Invited, JP.
- 2013. Oncology Practice in United States. Invited, JP.
- 2010. Comparative analysis of residency training between Japan and United States. Invited, JP.
Grant & Contract Support
| Date: | 2025 - 2026 |
| Title: | Targeting HOX/MEIS pathway with Menin Inhibitor in Chronic Myelomonocytic Leukemia (CMML) |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | PI |
| Date: | 2023 - 2028 |
| Title: | Improving efficacy of Menin Inhibitor-based therapy of AML |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | FP00018561 |
| Date: | 2023 - 2028 |
| Title: | Improving efficacy of Menin Inhibitor-based therapy of AML |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | FP00018561 |
| Date: | 2023 - 2026 |
| Title: | Development of Targeted Therapy for Myeloid Neoplasms with Deletion 7q |
| Funding Source: | Leukemia and Lymphoma Society |
| Role: | PI |
| ID: | FP00018512 |
| Date: | 2022 - 2025 |
| Title: | Targeting Clonal Hematopoiesis (CH) to Prevent Acute Myeloid Leukemia (AML) |
| Funding Source: | Break Through Cancer |
| Role: | PI |
| ID: | PA12-0305, PA-0345 |
| Date: | 2022 - 2027 |
| Title: | Mutual Reinforcement between Somatic Mutations and Transcription Factors in Clonal Hematopoiesis |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | FP00016109 / TAMU ID: 2203832 |
| Date: | 2022 - 2023 |
| Title: | Impact of Chemotherapy on Hematopoietic Stem Cell Clonality and Its Association with Clonal Hematopoiesis and Therapy-Related Myeloid Neoplasms |
| Funding Source: | UTMDACC MDS/AML Moon Shot – Project 4 |
| Role: | PI |
| Date: | 2022 - 2025 |
| Title: | Molecular Pathogenesis and Therapeutic Vulnerabilities of Myelodysplastic Syndrome with del7q/-7 |
| Funding Source: | Edward P. Evans Foundation |
| Role: | PI |
| ID: | FP00016363 |
| Date: | 2022 - 2027 |
| Title: | Understanding the Clonal Origin, Evolution, and Progression of Myeloid Malignancies |
| Funding Source: | Leukemia & Lymphoma Society CDP Scholar Award |
| Role: | PI |
| ID: | FP00015572 |
| Date: | 2022 - 2027 |
| Title: | Biology and efficacy of Menin Inhibitors in AML therapy |
| Funding Source: | NIH/NCI |
| Role: | CO-I |
| ID: | FP00015061/13474266 |
| Date: | 2022 - 2027 |
| Title: | Mutual Reinforcement between Somatic Mutations and Transcription Factors in Clonal Hematopoiesis |
| Funding Source: | NIH/NCI |
| Role: | CO-I |
| ID: | FP00014075 |
| Date: | 2022 - 2027 |
| Title: | Measurable Residual Disease Detection in Acute Myeloid Leukemia by Single-cell Multi-omics |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 13380570 |
| Date: | 2022 - 2025 |
| Title: | The INTERCEPT Trial (Investigating Novel Theraphy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy) for Acute Myeloid Leukemia |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | CO-I |
| ID: | RP220299 |
| Date: | 2022 - 2025 |
| Title: | Mutual Reinforcement between Somatic Mutations and Transcription Factors in Hematological Malignancies |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | CO-I |
| Date: | 2022 - 2025 |
| Title: | Measurable Residual Disease (MRD) Detection in Acute Myeloid Leukemia by Single-cell Multi-omics |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| Date: | 2021 - 2023 |
| Title: | The Role of HIPK2 in the Pathogenesis of Therapy-Related Myelodysplastic Syndrome with del7q |
| Funding Source: | Dresner Foundation |
| Role: | PI |
| ID: | FP0001433 |
| Date: | 2021 - 2024 |
| Title: | Measurable Residual Disease (MRD) Detection in Acute Myeloid Leukemia by Single-cell Multi-omics |
| Funding Source: | Leukemia and Lymphoma Society |
| Role: | PI |
| ID: | FP00013624 |
| Date: | 2021 - 2026 |
| Title: | Preventing Leukemia and MDS by Addressing Environmental Drivers of Clonal Hematopoiesis |
| Funding Source: | Leukemia and Lymphoma Society |
| Role: | Collaborator |
| ID: | SCOR-20649-20 |
| Date: | 2021 - 2026 |
| Title: | Modifiable Drivers of Expansion and Malignant Transformation from Clonal Hematopoiesis. Project 3: Contribution of Inflammation and DNA Damaging Factors to Clonal Expansion and Malignant Transformation in a Community Cohort of Older Adults |
| Funding Source: | NIH/NCI |
| Role: | Co-Project Leader |
| ID: | FP00012779 |
| Date: | 2021 - 2026 |
| Title: | Modifiable Drivers of Expansion and Malignant Transformation from Clonal Hematopoiesis. Core A: Single Cell Profiling and Bioinformatics Core |
| Funding Source: | NIH/NCI |
| Role: | Core Leader |
| ID: | 1 P01 CA265748 |
| Date: | 2021 - 2025 |
| Title: | Novel targeted therapies of AML stem-progenitor cells |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | FP00013115 |
| Date: | 2021 - 2022 |
| Title: | Elucidating Evolutionary History of Clonal Hematopoiesis |
| Funding Source: | UTMDACC MDS/AML Moon Shot - Project 4 |
| Role: | CO-I |
| Date: | 2021 - 2023 |
| Title: | Measurable Residual Disease (MRD) Detection Using Single Cell Multiomics in Patients with Acute Myeloid Leukemia |
| Funding Source: | UTMDACC Institutional Research Grant |
| Role: | Co-PI |
| Date: | 2021 - 2025 |
| Title: | Novel targeted therapies of AML stem-progenitor cells |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | FP00013115 |
| Date: | 2021 - 2022 |
| Title: | Elucidating the Clonal Origin and Evolutionary History of Clonal Hematopoiesis of Indeterminate Potential (CHIP) |
| Funding Source: | Dressner |
| Role: | PI |
| ID: | FP00008822 |
| Date: | 2021 - 2025 |
| Title: | Novel combination therapy for AML expressing mutant RUNX1 |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | 1RO1CA262636 |
| Date: | 2021 - 2023 |
| Title: | Mapping the Genetic and Phenotypic Heterogeneity in AML and Its Clinical Significance |
| Funding Source: | American Society of Hematology (ASH) |
| Role: | PI |
| ID: | FP00008946 |
| Date: | 2021 - 2025 |
| Title: | Novel combination therapy for AML expressing mutant RUNX1 |
| Funding Source: | NIH/NIAMS |
| Role: | Research Scientist |
| ID: | 13215712 |
| Date: | 2021 - 2023 |
| Title: | Understanding the Genetic Predisposition and the Role of Chemo-radiation Exposures for Therapy-related Myeloma Neoplasms |
| Funding Source: | V Foundation |
| Role: | PI |
| Date: | 2021 - 2023 |
| Title: | Evolutionary Timing and Genetic Determinants of AML Transformation |
| Funding Source: | Gabrielle’s Angel Foundation for Cancer Research |
| Role: | PI |
| ID: | FP00011843 |
| Date: | 2020 - 2021 |
| Title: | UTMDACC Leukemia SPORE Development Award:: Mapping the genetic and phenotypic heterogeneity in AML and its clinical significance |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | P50 CA100632-18 |
| Date: | 2020 - 2022 |
| Title: | Clonal Diversity in Acute Myeloid Leukemia (AML) and Its Clinical Implications |
| Funding Source: | The Andrew Sabin Family Foundation Fellowship |
| Role: | PI |
| Date: | 2020 - 2023 |
| Title: | Targeting Anti-Apoptotic Pathways in MDS at that time of Progression |
| Funding Source: | Evans MDS |
| Role: | Collaborator |
| Date: | 2020 - 2025 |
| Title: | Precision Identification of Resistant and Relapse-causing Subclones in AML Treated with Decitabine and Venetoclax |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1RO1CA255067-01 (Tracking #13009658) |
| Date: | 2020 - 2021 |
| Title: | Elucidating the role of immune microenvironment in the progression of clonal hematopoiesis |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| Date: | 2020 - 2023 |
| Title: | Precision Characterization of Clonal Diversity in AML and its Clinical Implications |
| Funding Source: | The Leukemia & Lymphoma Society |
| Role: | PI |
| Date: | 2020 - 2022 |
| Title: | Precision Characterization of Clonal Diversity in AML and Its Clinical Implications |
| Funding Source: | Emerson Collective |
| Role: | PI |
| Date: | 2019 - 2020 |
| Title: | UTMDACC Leukemia SPORE Development Award: Optimization and advancement of molecular MRD detection in AML |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | P50 CA100632-17 |
| Date: | 2019 - 2024 |
| Title: | PPM1D in clonal hematopoiesis and malignancies |
| Funding Source: | Baylor College of Medicine |
| Role: | CO-I |
| ID: | R01CA237291 |
| Date: | 2019 - 2019 |
| Title: | Development of Single-Cell MRD Assay |
| Funding Source: | Agilent Technologies |
| Role: | PI |
| Date: | 2018 - 2021 |
| Title: | Investigating the mechanism of resistance to IDH inhibitor in AML |
| Funding Source: | Conquer Cancer Foundation |
| Role: | PI |
| Date: | 2018 - 2019 |
| Title: | Characterizing clonal heterogeneity and remodeling of AML with single cell DNA sequencing |
| Funding Source: | Leukemia Research Foundation |
| Role: | PI |
| ID: | FP5083 |
| Date: | 2018 - 2020 |
| Title: | Preventing therapy-related leukemia and myelodysplastic syndromes |
| Funding Source: | NIH/NCI |
| Role: | CO-I |
| ID: | FP00002896 |
| Date: | 2018 - 2021 |
| Title: | Characterizing clonal evolution and epigenomic reprogramming during IDH inhibitor therapy in acute myeloid leukemia (AML) |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RP180489 |
| Date: | 2018 - 2019 |
| Title: | Characterizing clonal architecture and epigeneticremodeling of CHIP |
| Funding Source: | Gilead Sciences Inc |
| Role: | PI |
| Date: | 2017 - 2019 |
| Title: | Characterizing clonal architecture and heterogeneity of clonal hematopoiesis of indeterminate |
| Funding Source: | Dresner Foundation |
| Role: | PI |
| Date: | 2017 - 2020 |
| Title: | Identifying patients at risk of developing therapy-related myeloid neoplasms |
| Funding Source: | Leukemia and Lymphoma Society |
| Role: | PI |
| ID: | FP00001771 |
| Date: | 2017 - 2021 |
| Title: | Physician Scientist Program Award |
| Funding Source: | MD Anderson Cancer Center |
| Role: | PI |
| Date: | 2017 - 2022 |
| Title: | Start Up Funds for Tenure-Track Faculty |
| Funding Source: | MD Anderson Cancer Center |
| Role: | PI |
| Date: | 2017 - 2019 |
| Title: | Understanding the mechanism of clonal evolution of CHiP to t-MDS |
| Funding Source: | EvansMDS Foundation |
| Role: | CO-I |
| Date: | 2017 - 2018 |
| Title: | Improving Prediction of Relapse in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Using Next-Generation Sequencing |
| Funding Source: | Conquer Cancer Foundation |
| Role: | CO-I |
| ID: | FP00000098 |
| Date: | 2017 - 2018 |
| Title: | Targeting clonal hematopoiesis to prevent therapy related myeloid neoplasms |
| Funding Source: | Leukemia Research Foundation |
| Role: | PI |
| ID: | FP00001936 |
| Date: | 2016 - 2018 |
| Title: | Early detection of therapy-related myeloid neoplasms using clonal hematopoiesis as a biomarker |
| Funding Source: | Khalifa Scholar Award at The University of Texas MD Anderson Cancer Center |
| Role: | PI |
| Date: | 2016 - 2017 |
| Title: | Investigating Clinical Implication of Antecedent Clonal Hematopoiesis in t-AML/t-MDS |
| Funding Source: | UTMDACC Leukemia SPORE Career Enhancement Program |
| Role: | PI |
| Date: | 2016 - 2017 |
| Title: | NO TITLE PROVIDED |
| Funding Source: | Ladies Leukemia League |
| Role: | PI |
| Date: | 2016 - 2017 |
| Title: | Clonal hematopoiesis in cancer patients predicts development of therapy-related AML/MDS |
| Funding Source: | Institutional Research Grant at The University of Texas MD Anderson Cancer Center |
| Role: | PI |
| Date: | 2016 - 2016 |
| Title: | Investigating Clinical Implication of Antecedent Clonal Hematopoiesis in t-AML/t-MDS |
| Funding Source: | Mike Hogg Fund |
| Role: | PI |
| ID: | 1 |
| Date: | 2016 - 2017 |
| Title: | Identifying biomarkers that predict developments of therapy-related AML/MDS |
| Funding Source: | Sabin Fellows Award |
| Role: | PI |
| Date: | 2015 - 2017 |
| Title: | Improving the recognition, treatment, and prevention strategies for patients with inherited predispositions to hematologic malignancies |
| Funding Source: | UTMDACC Leukemia SPORE Career Enhancement Award |
| Role: | Co-PI |
| ID: | P50 CA100632 |
| Date: | 2015 - 2017 |
| Title: | UTMDACC Leukemia SPORE Career Development Award: Investigating Clinical Implication of Antecedent Clonal Hematopoiesis in t-AML/t-MDS |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | P50CA100632 |
| Date: | 2015 - 2017 |
| Title: | Clonal hematopoiesis in cancer patients predicts development of AML/MDS |
| Funding Source: | Red and Charline McCombs Institute Center for Global Cancer Early Detection at The University of Texas MD Anderson Cancer Center |
| Role: | PI |
| ID: | 00 |
| Title: | Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Translational Collaborator |
Selected Publications
Peer-Reviewed Articles
- Fiskus, WC, Mill, CP, Piel, J, Collins, M, Hentemann, M, Cuglievan, B, Birdwell, C, Das, K, Hou, H, Davis, JA, Jain, A, Malovannaya, A, Kadia, TM, Daver, N, Sasaki, K, Takahashi, K, Hammond, D, Reville, PK, Flores, L, Loghavi, S, Su, X, DiNardo, C, Bhalla, K. Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations. Blood cancer journal 15(1), 2025. e-Pub 2025. PMID: 40089460.
- Shi, X, Li, M, Liu, Z, Tiessen, J, Li, Y, Zhou, J, Zhu, Y, Mahesula, S, Ding, Q, Tan, L, Feng, M, Kageyama, Y, Hara, Y, Tao, JJ, Luo, X, Patras, KA, Lorenzi, PL, Huang, S, Stevens, A, Takahashi, K, Issa, GC, Samee, MH, Agathocleous, M, Nakada, D. Guanine nucleotide biosynthesis blockade impairs MLL complex formation and sensitizes leukemias to menin inhibition. Nature communications 16(1), 2025. e-Pub 2025. PMID: 40102405.
- Rodriguez-Sevilla, JJ, Ganan Gomez, I, Kumar, B, Thongon, N, Ma, F, Chien, KS, Kim, YJ, Yang, H, Loghavi, S, Tan, R, Ademà Llobet, V, Li, Z, Tanaka, T, Uryu, H, Kanagal Shamanna, R, Al-Atrash, G, Bejar, R, Banerjee, PP, Lynn Cha, S, Montalban Bravo, G, Dougherty, M, Fernandez Laurita, MC, Wheeler, N, Jia, B, Papapetrou, EP, Izzo, F, Duenas, DE, McAllen, S, Gu, Y, Todisco, G, Ficara, F, Della Porta, M, Jain, A, Takahashi, K, Dwyer, KC, Halene, S, Bertilaccio, MS, Garcia-Manero, G, Daher, M, Colla, S. Natural killer cells’ functional impairment drives the immune escape of pre-malignant clones in early-stage myelodysplastic syndromes. Nature communications 16(1), 2025. e-Pub 2025. PMID: 40216768.
- Bayer, F, Roncador, M, Moffa, G, Morita, K, Takahashi, K, Beerenwinkel, N, Kuipers, J. Network-based clustering unveils interconnected landscapes of genomic and clinical features across myeloid malignancies. Nature communications 16(1), 2025. e-Pub 2025. PMID: 40301336.
- Short, NJ, Kantarjian, HM, Furudate, K, Jain, N, Ravandi-Kashani, F, Karrar, OS, Loghavi, S, Nasr, L, Haddad, FG, Senapati, J, Garris, R, Takahashi, K, Jabbour, EJ. Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomab. Journal of Hematology and Oncology 18(1), 2025. e-Pub 2025. PMID: 40369607.
- Luo XG, Kuipers J, Rupp K, Takahashi K, Beerenwinkel N. Bayesian inference of fitness landscapes via tree-structured branching processes. Bioinformatics 41(Supplement_1):i160-i169, 2025. e-Pub 2025. PMID: 40662787.
- Mitchell E, Pham MH, Clay A, Sanghvi R, Williams N, Pietsch S, Hsu JI, Jung H, Vedi A, Moody S, Wang J, Leonganmornlert D, Spencer Chapman M, Dunstone E, Santarsieri A, Cagan A, Machado HE, Baxter EJ, Follows G, Hodson DJ, McDermott U, Doherty GJ, Martincorena I, Humphreys L, Mahbubani K, Saeb Parsy K, Takahashi K, Goodell MA, Kent D, Laurenti E, Campbell PJ, Rahbari R, Nangalia J, Stratton MR. The long-term effects of chemotherapy on normal blood cells. Nat Genet, 2025. e-Pub 2025. PMID: 40596443.
- Uryu H, Saeki K, Haeno H, Kapadia CD, Furudate K, Nangalia J, Spencer Chapman M, Zhao L, Hsu JI, Zhao C, Chen S, Tanaka T, Li Z, Ogata S, Hanache S, Yang H, DiNardo C, Daver N, Pemmaraju N, Jain N, Ravandi F, Zhang J, Song X, Thompson E, Tang H, Little L, Gumbs C, Orlowski RZ, Qazilbash M, Bhalla K, Colla S, Kantarjian H, Kanagal-Shamanna R, Bueso-Ramos C, Nakada D, Al-Atrash G, Molldrem J, Futreal PA, Shpall E, Goodell M, Garcia-Manero G, Takahashi K. Clonal evolution of hematopoietic stem cells after autologous stem cell transplantation. Nat Genet, 2025. e-Pub 2025. PMID: 40596442.
- Bouligny IM, Montalban-Bravo G, Sasaki K, Daver N, Jabbour E, Alvarado Y, DiNardo CD, Ravandi F, Borthakur G, Bose P, Pemmaraju N, Kornblau S, Kadia T, Masarova L, Takahashi K, Andreeff M, Bazinet A, Yang H, Kanagal-Shamanna R, Hosing C, Pierce S, Meyer M, Huang X, Garcia-Manero G. A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome. Haematologica 110(7):1628-1633, 2025. e-Pub 2025. PMID: 39973365.
- DiNardo CD, Marvin-Peek J, Loghavi S, Takahashi K, Issa GC, Jen WY, Daver NG, Reville PK, Short NJ, Sasaki K, Mullin JK, Bradley CA, Borthakur G, Maiti A, Alvarado Y, Pemmaraju N, Abbas HA, Hammond DE, Haddad F, Bravo GM, Chien KS, Yilmaz M, Kornblau SM, Jabbour E, Ravandi F, Kadia T, Garcia-Manero G, Konopleva MY, Kantarjian HM. Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML. J Clin Oncol:JCO2500640, 2025. e-Pub 2025. PMID: 40513054.
- Veletic, I, Harris, D, Rozovski, U, Bertilaccio, MS, Calin, GA, Takahashi, K, Li, P, Liu, Z, Manshouri, T, Drula, R, Furudate, K, Muftuoglu, M, Hossain, A, Wierda, WG, Keating, M, Estrov, Z. CLL cell-derived exosomes alter the immune and hematopoietic systems. Leukemia 39(6):1380-1394, 2025. e-Pub 2025. PMID: 40186065.
- DiNardo, C, Jen, WY, Takahashi, K, Kadia, TM, Loghavi, S, Daver, N, Xiao, L, Reville, PK, Issa, GC, Short, NJ, Sasaki, K, Wang, S, Mullin, JK, Pierce, S, Bradley, C, Borthakur, G, Maiti, A, Alvarado, Y, Pemmaraju, N, Ferrajoli, A, Swaminathan, M, Ohanian, M, Abbas, HA, Hammond, D, Burger, JA, Haddad, FG, Montalban Bravo, G, Chien, KS, Masarova, L, Yilmaz, M, Jain, N, Andreeff, M, Garcia-Manero, G, Kornblau, SM, Ravandi-Kashani, F, Jabbour, EJ, Konopleva, M, Kantarjian, HM. Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia. Leukemia 39(4):854-863, 2025. e-Pub 2025. PMID: 40000842.
- Jen, WY, Marvin-Peek, J, Kantarjian, HM, Alvarado, Y, Borthakur, G, Jabbour, EJ, Wierda, WG, Kadia, TM, Daver, N, DiNardo, C, Short, NJ, Jain, N, Ferrajoli, A, Kornblau, SM, Yilmaz, M, Ohanian, M, McCue, D, Burger, JA, Hammond, DE, Patel, K, Issa, GC, Pemmaraju, N, Sasaki, K, Maiti, A, Abbas, HA, Chien, KS, Takahashi, K, Haddad, FG, Bose, P, Masarova, L, Montalban Bravo, G, Swaminathan, M, Brandt, M, Pierce, S, Garcia-Manero, G, Ravandi, F. Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia. Cancer 131(1), 2025. e-Pub 2025. PMID: 39584789.
- Senapati J, Loghavi S, Garcia-Manero G, Tang G, Kadia T, Short NJ, Abbas HA, Arani N, DiNardo CD, Borthakur G, Pemmaraju N, Oran B, Shpall E, Popat U, Champlin R, Pierce S, Arora S, Issa G, Yilmaz M, Patel K, Takahashi K, Montalban-Bravo G, Hammond D, Haddad FG, Ravandi F, Kantarjian HM, Daver NG. Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasms. Haematologica, 2024. e-Pub 2024. PMID: 39665206.
- Mill, CP, Fiskus, WC, DiNardo, C, Reville, PK, Davis, JA, Birdwell, C, Das, K, Hou, H, Takahashi, K, Flores, L, Ruan, X, Su, X, Loghavi, S, Khoury, J, Bhalla, K. Efficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM). Blood cancer journal 14(1), 2024. e-Pub 2024. PMID: 38316746.
- Tseng, YJ, Kageyama, Y, Murdaugh, RL, Kitano, A, Kim, JH, Hoegenauer, KA, Tiessen, J, Smith, MH, Uryu, H, Takahashi, K, Martin, JF, Samee, MH, Nakada, D. Increased iron uptake by splenic hematopoietic stem cells promotes TET2-dependent erythroid regeneration. Nature communications 15(1), 2024. e-Pub 2024. PMID: 38225226.
- Tseng, YJ, Kageyama, Y, Murdaugh, RL, Kitano, A, Kim, JH, Hoegenauer, KA, Tiessen, J, Smith, MH, Uryu, H, Takahashi, K, Martin, JF, Samee, MH, Nakada, D. Increased iron uptake by splenic hematopoietic stem cells promotes TET2-dependent erythroid regeneration. Nature communications 15(1), 2024. e-Pub 2024. PMID: 38225226.
- Thongon, N, Ma, F, Baran, N, Lockyer, P, Liu, J, Jackson, C, Rose, A, Furudate, K, Wildeman, B, Marchesini, M, Marchica, V, Storti, P, Todaro, G, Ganan Gomez, I, Ademà Llobet, V, Rodriguez-Sevilla, JJ, Qing, Y, Ha, MJ, Fonseca, R, Stein, C, Class, CA, Tan, L, Attanasio, S, Garcia-Manero, G, Giuliani, N, Berrios Nolasco, DA, Santoni, A, Cerchione, C, Bueso-Ramos, CE, Konopleva, M, Lorenzi, PL, Takahashi, K, Manasanch, EE, Sammarelli, G, Kanagal Shamanna, R, Viale, A, Chesi, M, Colla, S. Targeting DNA2 overcomes metabolic reprogramming in multiple myeloma. Nature communications 15(1), 2024. e-Pub 2024. PMID: 38331987.
- Thongon, N, Ma, F, Baran, N, Lockyer, P, Liu, J, Jackson, C, Rose, A, Furudate, K, Wildeman, B, Marchesini, M, Marchica, V, Storti, P, Todaro, G, Ganan Gomez, I, Ademà Llobet, V, Rodriguez-Sevilla, JJ, Qing, Y, Ha, MJ, Fonseca, R, Stein, C, Class, CA, Tan, L, Attanasio, S, Garcia-Manero, G, Giuliani, N, Berrios Nolasco, DA, Santoni, A, Cerchione, C, Bueso-Ramos, CE, Konopleva, M, Lorenzi, PL, Takahashi, K, Manasanch, EE, Sammarelli, G, Kanagal Shamanna, R, Viale, A, Chesi, M, Colla, S. Targeting DNA2 overcomes metabolic reprogramming in multiple myeloma. Nature communications 15(1), 2024. e-Pub 2024. PMID: 38331987.
- Bouligny IM, Montalban-Bravo G, Sasaki K, Daver N, Jabbour E, Alvarado Y, DiNardo CD, Ravandi F, Borthakur G, Pemmaraju N, Kadia T, Masarova L, Takahashi K, Andreeff M, Bazinet A, Yang H, Kanagal R, Pierce S, Meyer M, Huang X, Garcia-Manero G. A phase II trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in relapsed or refractory myelodysplastic neoplasms. Leukemia 39(2):524-528, 2024. e-Pub 2024. PMID: 39551874.
- Bataller Torralba, A, Kantarjian, H, Bazinet, A, Kadia, TM, Daver, N, DiNardo, CD, Borthakur, G, Loghavi, S, Patel, K, Tang, G, Sasaki, K, Short, NJ, Yilmaz, M, Issa, GC, Alvarado, Y, Montalban-Bravo, G, Maiti, A, Abbas, HA, Takahashi, K, Pierce, S, Jabbour, EJ, Garcia-Manero, G, Ravandi, F. Outcomes and genetic dynamics of acute myeloid leukemia at first relapse. Haematologica 109(11):3543-3556, 2024. e-Pub 2024. PMID: 38695144.
- Bataller Torralba, A, Kantarjian, H, Bazinet, A, Kadia, TM, Daver, N, DiNardo, CD, Borthakur, G, Loghavi, S, Patel, K, Tang, G, Sasaki, K, Short, NJ, Yilmaz, M, Issa, GC, Alvarado, Y, Montalban-Bravo, G, Maiti, A, Abbas, HA, Takahashi, K, Pierce, S, Jabbour, EJ, Garcia-Manero, G, Ravandi, F. Outcomes and genetic dynamics of acute myeloid leukemia at first relapse. Haematologica 109(11):3543-3556, 2024. e-Pub 2024. PMID: 38695144.
- Schwede, M, Jahn, K, Kuipers, J, Miles, LA, Bowman, RL, Robinson, T, Furudate, K, Uryu, H, Tanaka, T, Sasaki, Y, Ediriwickrema, A, Benard, B, Gentles, AJ, Levine, RL, Beerenwinkel, N, Takahashi, K, Majeti, R. Mutation order in acute myeloid leukemia identifies uncommon patterns of evolution and illuminates phenotypic heterogeneity. Leukemia 38(7):1501-1510, 2024. e-Pub 2024. PMID: 38467769.
- Zhang, L, Hsu, JI, Braekeleer, ED, Chen, CW, Patel, TD, Martell, AG, Guzman, A, Wohlan, K, Waldvogel, S, Uryu, H, Tovy, A, Callen, E, Murdaugh, RL, Richard, R, Jansen, S, Vissers, LE, de Vries, BB, Nussenzweig, A, Huang, S, Coarfa, C, Anastas, J, Takahashi, K, Vassiliou, G, Goodell, MA. SOD1 is a synthetic-lethal target in PPM1D-mutant leukemia cells. eLife 12, 2024. e-Pub 2024. PMID: 38896450.
- Bataller, A, Gener-Ricos, G, Almanza-Huante, E, Chien, KS, Urrutia, S, Bazinet, A, Rodriguez-Sevilla, JJ, Hammond, DE, Sasaki, K, Takahashi, K, DiNardo, C, Ravandi-Kashani, F, Borthakur, G, Kadia, TM, Kanagal Shamanna, R, Kantarjian, HM, Garcia-Manero, G, Montalban Bravo, G. Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm. Blood Advances 8(11):2695-2706, 2024. e-Pub 2024. PMID: 38513082.
- Dinh, A, Savoy, JM, Kontoyiannis, DP, Takahashi, K, Issa, GC, Kantarjian, HM, DiNardo, C, Rausch, CR. Ivosidenib significantly reduces triazole levels in patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer 130(11):1964-1971, 2024. e-Pub 2024. PMID: 38340331.
- Fiskus, WC, Piel, J, Collins, M, Hentemann, M, Cuglievan, B, Mill, CP, Birdwell, C, Das, K, Davis, JA, Hou, H, Jain, A, Malovannaya, A, Kadia, TM, Daver, N, Sasaki, K, Takahashi, K, Hammond, DE, Reville, PK, Wang, J, Loghavi, S, Sen, R, Ruan, X, Su, X, Flores, L, DiNardo, C, Bhalla, K. BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor. Blood 143(20):2059-2072, 2024. e-Pub 2024. PMID: 38437498.
- Bataller, A, Bazinet, A, DiNardo, C, Maiti, A, Borthakur, G, Daver, N, Short, NJ, Jabbour, EJ, Issa, GC, Pemmaraju, N, Yilmaz, M, Montalban Bravo, G, Takahashi, K, Loghavi, S, Garcia-Manero, G, Ravandi-Kashani, F, Kantarjian, HM, Kadia, TM. Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax. Blood Advances 8(4):927-935, 2024. e-Pub 2024. PMID: 38113472.
- Morishima, T, Takahashi, K, Chin, DL, Wang, Y, Tokunaga, K, Arima, Y, Matsuoka, M, Suda, T, Takizawa, H. Phospholipid metabolic adaptation promotes survival of IDH2 mutant acute myeloid leukemia cells. Cancer science 115(1):197-210, 2024. e-Pub 2024. PMID: 37882467.
- Fiskus, WC, Mill, CP, Birdwell, C, Davis, JA, Das, K, Boettcher, S, Kadia, TM, DiNardo, C, Takahashi, K, Loghavi, S, Soth, MJ, Heffernan, TP, McGeehan, G, Ruan, X, Su, X, Vakoc, CR, Daver, N, Bhalla, K. Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1. Blood cancer journal 13(1), 2023. e-Pub 2023. PMID: 37055414.
- Chen, CW, Zhang, L, Dutta, R, Niroula, A, Miller, PG, Gibson, CJ, Bick, AG, Reyes, JM, Lee, YT, Tovy, A, Gu, T, Waldvogel, S, Chen, YH, Venters, BJ, Estève, PO, Pradhan, S, Keogh, MC, Natarajan, P, Takahashi, K, Sperling, AS, Goodell, MA. SRCAP mutations drive clonal hematopoiesis through epigenetic and DNA repair dysregulation. Cell Stem Cell 30(11):1503-1519.e8, 2023. e-Pub 2023. PMID: 37863054.
- Strati P, Li X, Deng Q, Marques-Piubelli ML, Henderson J, Watson G, Deaton L, Cain T, Yang H, Ravanmehr V, Fayad LE, Iyer SP, Nastoupil LJ, Hagemeister FB, Parra ER, Saini N, Takahashi K, Fowler NH, Westin JR, Steiner RE, Nair R, Flowers CR, Wang L, Ahmed S, Al-Atrash G, Vega F, Neelapu SS, Green MR. Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFNγ-expressing CD8 T cells. Cell Rep Med 4(8):101158, 2023. e-Pub 2023. PMID: 37586321.
- Sollier E, Kuipers J, Takahashi K, Beerenwinkel N, Jahn K. COMPASS: joint copy number and mutation phylogeny reconstruction from amplicon single-cell sequencing data. Nat Commun 14(1):4921, 2023. e-Pub 2023. PMID: 37582954.
- Lee, SE, Wang, F, Grefe, M, Trujillo-Ocampo, A, Ruiz-Vasquez, W, Takahashi, K, Abbas, HA, Borges, P, Antunes, DA, Al-Atrash, G, Daver, N, Molldrem, JJ, Futreal, A, Garcia-Manero, G, Im, JS. Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic Syndromes. Clinical Cancer Research 29(10):1938-1951, 2023. e-Pub 2023. PMID: 36988276.
- Bazinet A, Darbaniyan F, Jabbour E, Montalban-Bravo G, Ohanian M, Chien K, Kadia T, Takahashi K, Masarova L, Short N, Alvarado Y, Yilmaz M, Ravandi F, Andreeff M, Kanagal-Shamanna R, Ganan-Gomez I, Colla S, Qiao W, Huang X, McCue D, Mirabella B, Kantarjian H, Garcia-Manero G. Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study. Lancet Haematol 9(10):e756-e765, 2022. e-Pub 2022. PMID: 36063832.
- Baran N, Lodi A, Dhungana Y, Herbrich S, Collins M, Sweeney S, Pandey R, Skwarska A, Patel S, Tremblay M, Kuruvilla VM, Cavazos A, Kaplan M, Warmoes MO, Veiga DT, Furudate K, Rojas-Sutterin S, Haman A, Gareau Y, Marinier A, Ma H, Harutyunyan K, Daher M, Garcia LM, Al-Atrash G, Piya S, Ruvolo V, Yang W, Shanmugavelandy SS, Feng N, Gay J, Du D, Yang JJ, Hoff FW, Kaminski M, Tomczak K, Eric Davis R, Herranz D, Ferrando A, Jabbour EJ, Emilia Di Francesco M, Teachey DT, Horton TM, Kornblau S, Rezvani K, Sauvageau G, Gagea M, Andreeff M, Takahashi K, Marszalek JR, Lorenzi PL, Yu J, Tiziani S, Hoang T, Konopleva M. Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia. Nat Commun 13(1):2801, 2022. e-Pub 2022. PMID: 35589701.
- Yilmaz M, Kantarjian H, Short NJ, Reville P, Konopleva M, Kadia T, DiNardo C, Borthakur G, Pemmaraju N, Maiti A, Jabbour E, Jain N, Issa G, Takahashi K, Sasaki K, Ohanian M, Pierce S, Tang G, Loghavi S, Patel K, Wang SA, Garcia-Manero G, Andreeff M, Ravandi F, Daver N. Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML. Blood Cancer J 12(5):77, 2022. e-Pub 2022. PMID: 35501304.
- Lachowiez CA, Reville PK, Kantarjian H, Jabbour E, Borthakur G, Daver N, Loghavi S, Furudate K, Xiao L, Pierce S, Short NJ, Maiti A, Yilmaz M, Sasaki K, Takahashi K, Konopleva M, Pemmaraju N, Popat U, Shpall E, Garcia-Manero G, Ravandi F, DiNardo CD, Kadia TM. Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. Lancet Haematol 9(5):e350-e360, 2022. e-Pub 2022. PMID: 35483396.
- Venugopal S, Takahashi K, Daver N, Maiti A, Borthakur G, Loghavi S, Short NJ, Ohanian M, Masarova L, Issa G, Wang X, Carlos BR, Yilmaz M, Kadia T, Andreeff M, Ravandi F, Konopleva M, Kantarjian HM, DiNardo CD. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy. Blood Cancer J 12(1):10, 2022. e-Pub 2022. PMID: 35078972.
- Fiskus W, Boettcher S, Daver N, Mill CP, Sasaki K, Birdwell CE, Davis JA, Takahashi K, Kadia TM, DiNardo CD, Jin Q, Qi Y, Su X, McGeehan GM, Khoury JD, Ebert BL, Bhalla KN. Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c). Blood Cancer J 12(1):5, 2022. e-Pub 2022. PMID: 35017466.
- Abbas HA, Hao D, Tomczak K, Barrodia P, Im JS, Reville PK, Alaniz Z, Wang W, Wang R, Wang F, Al-Atrash G, Takahashi K, Ning J, Ding M, Beird HC, Mathews JT, Little L, Zhang J, Basu S, Konopleva M, Marques-Piubelli ML, Solis LM, Parra ER, Lu W, Tamegnon A, Garcia-Manero G, Green MR, Sharma P, Allison JP, Kornblau SM, Rai K, Wang L, Daver N, Futreal A. Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. Nat Commun 12(1):6071, 2021. e-Pub 2021. PMID: 34663807.
- Shi X, Jiang Y, Kitano A, Hu T, Murdaugh RL, Li Y, Hoegenauer KA, Chen R, Takahashi K, Nakada D. Nuclear NAD+ homeostasis governed by NMNAT1 prevents apoptosis of acute myeloid leukemia stem cells. Sci Adv 7(30), 2021. e-Pub 2021. PMID: 34290089.
- Fiskus W, Mill CP, Nabet B, Perera D, Birdwell C, Manshouri T, Lara B, Kadia TM, DiNardo C, Takahashi K, Daver N, Bose P, Masarova L, Pemmaraju N, Kornblau S, Borthakur G, Montalban-Bravo G, Manero GG, Sharma S, Stubbs M, Su X, Green MR, Coarfa C, Verstovsek S, Khoury JD, Vakoc CR, Bhalla KN. Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells. Blood Cancer J 11(5):98, 2021. e-Pub 2021. PMID: 34016956.
- Wang F, Morita K, DiNardo CD, Furudate K, Tanaka T, Yan Y, Patel KP, MacBeth KJ, Wu B, Liu G, Frattini M, Matthews JA, Little LD, Gumbs C, Song X, Zhang J, Thompson EJ, Kadia TM, Garcia-Manero G, Jabbour E, Ravandi F, Bhalla KN, Konopleva M, Kantarjian HM, Andrew Futreal P, Takahashi K. Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia. Nat Commun 12(1):2607, 2021. e-Pub 2021. PMID: 33972549.
- Morita K, Wang F, Jahn K, Hu T, Tanaka T, Sasaki Y, Kuipers J, Loghavi S, Wang SA, Yan Y, Furudate K, Matthews J, Little L, Gumbs C, Zhang J, Song X, Thompson E, Patel KP, Bueso-Ramos CE, DiNardo CD, Ravandi F, Jabbour E, Andreeff M, Cortes J, Bhalla K, Garcia-Manero G, Kantarjian H, Konopleva M, Nakada D, Navin N, Beerenwinkel N, Futreal PA, Takahashi K. Author Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun 12(1):2823, 2021. e-Pub 2021. PMID: 33972555.
- Yilmaz M, Alfayez M, DiNardo CD, Borthakur G, Kadia TM, Konopleva MY, Loghavi S, Kanagal-Shamanna R, Patel KP, Jabbour EJ, Garcia-Manero G, Pemmaraju N, Pierce SA, Ghayas I, Short NJ, Montalban-Bravo G, Takahashi K, Assi R, Alotaibi AS, Ohanian M, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NG. Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol 14(1):34, 2021. e-Pub 2021. PMID: 33618754.
- Maiti A, DiNardo CD, Daver NG, Rausch CR, Ravandi F, Kadia TM, Pemmaraju N, Borthakur G, Bose P, Issa GC, Short NJ, Yilmaz M, Montalban-Bravo G, Ferrajoli A, Jabbour EJ, Jain N, Ohanian M, Takahashi K, Thompson PA, Loghavi S, Montalbano KS, Pierce S, Wierda WG, Kantarjian HM, Konopleva MY. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood Cancer J 11(2):25, 2021. e-Pub 2021. PMID: 33563904.
- Morita K, Wang F, Jahn K, Hu T, Tanaka T, Sasaki Y, Kuipers J, Loghavi S, Wang SA, Yan Y, Furudate K, Matthews J, Little L, Gumbs C, Zhang J, Song X, Thompson E, Patel KP, Bueso-Ramos CE, DiNardo CD, Ravandi F, Jabbour E, Andreeff M, Cortes J, Bhalla K, Garcia-Manero G, Kantarjian H, Konopleva M, Nakada D, Navin N, Beerenwinkel N, Futreal PA, Takahashi K. Publisher Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun 11(1):5996, 2020. e-Pub 2020. PMID: 33214561.
- Morita K, Wang F, Jahn K, Hu T, Tanaka T, Sasaki Y, Kuipers J, Loghavi S, Wang SA, Yan Y, Furudate K, Matthews J, Little L, Gumbs C, Zhang J, Song X, Thompson E, Patel KP, Bueso-Ramos CE, DiNardo CD, Ravandi F, Jabbour E, Andreeff M, Cortes J, Bhalla K, Garcia-Manero G, Kantarjian H, Konopleva M, Nakada D, Navin N, Beerenwinkel N, Futreal PA, Takahashi K. Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun 11(1):5327, 2020. e-Pub 2020. PMID: 33087716.
- Yilmaz M, Alfayez M, DiNardo CD, Borthakur G, Kadia TM, Konopleva MY, Loghavi S, Kanagal-Shamanna R, Patel KP, Jabbour EJ, Garcia-Manero G, Pemmaraju N, Pierce SA, Ghayas I, Short NJ, Montalban-Bravo G, Takahashi K, Assi R, Alotaibi AS, Ohanian M, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NG. Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol 13(1):132, 2020. e-Pub 2020. PMID: 33032648.
- DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol 7(10):e724-e736, 2020. e-Pub 2020. PMID: 32896301.
- Jabbour E, Richard-Carpentier G, Sasaki Y, Konopleva M, Patel K, Roberts K, Gu Z, Wang F, Huang X, Sasaki K, Short NJ, Jain N, Ravandi F, Daver NG, Kadia TM, Alvarado Y, DiNardo CD, Issa GC, Pemmaraju N, Garcia-Manero G, Verstovsek S, Wang S, Khoury JD, Jorgensen J, Champlin R, Khouri I, Kebriaei P, Schroeder H, Khouri M, Mullighan CG, Takahashi K, O'Brien SM, Kantarjian H. Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. Lancet Haematol 7(7):e523-e533, 2020. e-Pub 2020. PMID: 32589978.
- Ravandi F, Assi R, Daver N, Benton CB, Kadia T, Thompson PA, Borthakur G, Alvarado Y, Jabbour EJ, Konopleva M, Takahashi K, Kornblau S, DiNardo CD, Estrov Z, Flores W, Basu S, Allison J, Sharma P, Pierce S, Pike A, Cortes JE, Garcia-Manero G, Kantarjian HM. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. Lancet Haematol 6(9):e480-e488, 2019. e-Pub 2019. PMID: 31400961.
- Yilmaz M, Wang F, Loghavi S, Bueso-Ramos C, Gumbs C, Little L, Song X, Zhang J, Kadia T, Borthakur G, Jabbour E, Pemmaraju N, Short N, Garcia-Manero G, Estrov Z, Kantarjian H, Futreal A, Takahashi K, Ravandi F. Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?. Blood Cancer J 9(2):7, 2019. e-Pub 2019. PMID: 30651532.
- Takahashi K, Wang F, Morita K, Yan Y, Hu P, Zhao P, Zhar AA, Wu CJ, Gumbs C, Little L, Tippen S, Thornton R, Coyle M, Mendoza M, Thompson E, Zhang J, DiNardo CD, Jain N, Ravandi F, Cortes JE, Garcia-Manero G, Kornblau S, Andreeff M, Jabbour E, Bueso-Ramos C, Takaori-Kondo A, Konopleva M, Patel K, Kantarjian H, Futreal PA. Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes. Nat Commun 9(1):2670, 2018. e-Pub 2018. PMID: 29991687.
- Montalban-Bravo G, Takahashi K, Patel K, Wang F, Xingzhi S, Nogueras GM, Huang X, Pierola AA, Jabbour E, Colla S, Gañan-Gomez I, Borthakur G, Daver N, Estrov Z, Kadia T, Pemmaraju N, Ravandi F, Bueso-Ramos C, Chamseddine A, Konopleva M, Zhang J, Kantarjian H, Futreal A, Garcia-Manero G. Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. Oncotarget 9(11):9714-9727, 2018. e-Pub 2018. PMID: 29515765.
- Subbiah V, Grilley-Olson JE, Combest AJ, Sharma N, Tran RH, Bobe I, Osada A, Takahashi K, Balkissoon J, Camp A, Masada A, Reitsma DJ, Bazhenova LA. Phase Ib/II Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients with Advanced Solid Tumors. Clin Cancer Res 24(1):43-51, 2018. e-Pub 2018. PMID: 29030354.
- Boddu P, Kantarjian HM, Garcia-Manero G, Ravandi F, Verstovsek S, Jabbour E, Borthakur G, Konopleva M, Bhalla KN, Daver N, DiNardo CD, Benton CB, Takahashi K, Estrov Z, Pierce SR, Andreeff M, Cortes JE, Kadia TM. Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. Blood Adv 1(17):1312-1323, 2017. e-Pub 2017. PMID: 29296774.
- Takahashi K, Wang F, Kantarjian H, Song X, Patel K, Neelapu S, Gumbs C, Little L, Tippen S, Thornton R, DiNardo CD, Ravandi F, Bueso-Ramos C, Zhang J, Wu X, Garcia-Manero G, Futreal PA. Copy number alterations detected as clonal hematopoiesis of indeterminate potential. Blood Adv 1(15):1031-1036, 2017. e-Pub 2017. PMID: 29296745.
- Takahashi K, Patel K, Bueso-Ramos C, Zhang J, Gumbs C, Jabbour E, Kadia T, Andreff M, Konopleva M, DiNardo C, Daver N, Cortes J, Estrov Z, Futreal A, Kantarjian H, Garcia-Manero G. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. Oncotarget 7(12):14172-87, 2016. e-Pub 2016. PMID: 26871476.
- Kanagal-Shamanna R, Luthra R, Yin CC, Patel KP, Takahashi K, Lu X, Lee J, Zhao C, Stingo F, Zuo Z, Routbort MJ, Singh RR, Fox P, Ravandi F, Garcia-Manero G, Medeiros LJ, Bueso-Ramos CE. Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS. Oncotarget 7(12):14251-8, 2016. e-Pub 2016. PMID: 26883102.
Review Articles
- Takahashi, K, Nakada, D, Goodell, MA. Distinct landscape and clinical implications of therapy-related clonal hematopoiesis. Journal of Clinical Investigation 134(19), 2024. e-Pub 2024. PMID: 39352380.
- Takahashi K, Tanaka T. Clonal evolution and hierarchy in myeloid malignancies. Trends Cancer 9(9):707-715, 2023. e-Pub 2023. PMID: 37302922.
Professional Educational Materials
- Takahashi K. Management of clonal hematopoiesis in cancer patients, 2021.
Other Articles
- Fiskus, WC, Mill, CP, Birdwell, C, Davis, JA, Das, K, Boettcher, S, Kadia, TM, DiNardo, C, Takahashi, K, Loghavi, S, Soth, MJ, Heffernan, TP, McGeehan, G, Ruan, X, Su, X, Vakoc, CR, Daver, N, Bhalla, K Correction to. Blood cancer journal 15(1), 2025. PMID: 40399254.
Editorials
- Shah, N, Takahashi, K. Clonal hematopoiesis and solid tumor risk. Cancer 130(22):3800-3801, 2024. PMID: 39163274.
- Shah, N, Takahashi, K. Clonal hematopoiesis and solid tumor risk. Cancer 130(22):3800-3801, 2024. PMID: 39163274.
Letters to the Editor
- Chien, KS, Braish, J, Li, Z, Loghavi, S, Bataller Torralba, A, Montalban Bravo, G, Sasaki, K, Kanagal Shamanna, R, Takahashi, K, DiNardo, C, Swaminathan, M, Kantarjian, HM, Garcia-Manero, G. Clinicopathologic characteristics and outcomes of patients with clonal hematopoiesis who progress to myeloid neoplasms. Leukemia 39: 1269-1272, 2025.
- Zhou, T, Curry, CV, Khanlari, M, Shi, M, Cui, W, Peker, D, Chen, W, Wang, E, Gao, J, Shen, Q, Xie, W, Jelloul, FZ, King, RL, Yuan, J, Wang, X, Zhao, C, Obiorah, IE, Courville, E, Nomura, E, Cherian, S, Xu, ML, Burack, WR, Liu, Hx, Jabbour, EJ, Takahashi, K, Wang, W, Wang, SA, Khoury, J, Medeiros, LJ, Hu, S. Genetics and pathologic landscape of lineage switch of acute leukemia during therapy. Blood cancer journal 14, 2024.
- Abuasab, T, Borthakur, G, Kanagal Shamanna, R, Masarova, L, Patel, KP, Takahashi, K, Bose, P, Villarreal, J, Pierce, S, Kadia, TM, Garcia-Manero, G, Short, NJ, DiNardo, C, Daver, N, Ravandi-Kashani, F, Kantarjian, H, Verstovsek, S, Yilmaz, M. Exploring the landscape of somatic ASXL2 mutations in myeloid neoplasms. American journal of hematology 99: 1434-1436, 2024.
- Montalban Bravo, G, Rodriguez-Sevilla, JJ, Swanson, DM, Kanagal Shamanna, R, Hammond, DE, Chien, KS, Sasaki, K, Jabbour, EJ, DiNardo, C, Takahashi, K, Short, NJ, Issa, GC, Pemmaraju, N, Kadia, TM, Ravandi-Kashani, F, Daver, N, Borthakur, G, Loghavi, S, Pierce, S, Bueso-Ramos, CE, Kantarjian, HM, Garcia-Manero, G. Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia. Leukemia 38: 1178-1181, 2024.
- Hammond, DE, Loghavi, S, Wang, SA, Konopleva, M, Kadia, TM, Daver, N, Ohanian, M, Issa, GC, Alvarado, Y, Short, NJ, Sasaki, K, Pemmaraju, N, Montalban Bravo, G, Lachowiez, C, Maiti, A, Garcia-Manero, G, Jabbour, EJ, Borthakur, G, Ravandi-Kashani, F, Takahashi, K, Pierce, SR, Kantarjian, HM, DiNardo, C. Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents. Blood cancer journal 13, 2023.
Patient Reviews
CV information above last modified July 25, 2025